

# Joshua C Doloff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4465640/publications.pdf>

Version: 2024-02-01

35  
papers

3,902  
citations

331538

21  
h-index

395590

33  
g-index

40  
all docs

40  
docs citations

40  
times ranked

5299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. <i>Nature Materials</i> , 2015, 14, 643-651.	13.3	700
2	Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. <i>Nature Medicine</i> , 2016, 22, 306-311.	15.2	564
3	Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. <i>Nature Biotechnology</i> , 2016, 34, 345-352.	9.4	417
4	Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. <i>Nature Biotechnology</i> , 2019, 37, 1174-1185.	9.4	398
5	Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. <i>Nature Biomedical Engineering</i> , 2018, 2, 810-821.	11.6	242
6	Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates. <i>Nature Materials</i> , 2017, 16, 671-680.	13.3	214
7	Reduction of measurement noise in a continuous glucose monitor by coating the sensor with a zwitterionic polymer. <i>Nature Biomedical Engineering</i> , 2018, 2, 894-906.	11.6	150
8	Core-Shell Hydrogel Microcapsules for Improved Islets Encapsulation. <i>Advanced Healthcare Materials</i> , 2013, 2, 667-672.	3.9	141
9	The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. <i>Nature Biomedical Engineering</i> , 2021, 5, 1115-1130.	11.6	126
10	Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations. <i>Nature Materials</i> , 2019, 18, 892-904.	13.3	114
11	Enhanced function of immuno-isolated islets in diabetes therapy by co-encapsulation with an anti-inflammatory drug. <i>Biomaterials</i> , 2013, 34, 5792-5801.	5.7	96
12	Neutrophil Responses to Sterile Implant Materials. <i>PLoS ONE</i> , 2015, 10, e0137550.	1.1	92
13	Endothelial siRNA delivery in nonhuman primates using ionizable low molecular weight polymeric nanoparticles. <i>Science Advances</i> , 2018, 4, eaar8409.	4.7	81
14	VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression. <i>Cancer Research</i> , 2012, 72, 1103-1115.	0.4	79
15	Modular Click-Emulsion™ Bone-Targeted Nanogels. <i>Advanced Materials</i> , 2013, 25, 1449-1454.	11.1	73
16	Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression. <i>Neoplasia</i> , 2014, 16, 84-W27.	2.3	65
17	A Facile and Versatile Method to Endow Biomaterial Devices with Zwitterionic Surface Coatings. <i>Advanced Healthcare Materials</i> , 2017, 6, 1601091.	3.9	51
18	Conditionally Replicating Adenoviruses for Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2007, 7, 285-301.	0.8	45

#	ARTICLE	IF	CITATIONS
19	Human Telomerase Reverse Transcriptase Promoter-Driven Oncolytic Adenovirus with E1B-19 kDa and E1B-55 kDa Gene Deletions. <i>Human Gene Therapy</i> , 2008, 19, 1383-1399.	1.4	25
20	Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. <i>Molecular Cancer</i> , 2014, 13, 158.	7.9	24
21	Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6777.	1.8	23
22	Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. <i>Cancer Gene Therapy</i> , 2011, 18, 153-166.	2.2	21
23	Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementary Material). <i>Current Cancer Drug Targets</i> , 2009, 9, 777-788.	0.8	19
24	Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. <i>BMC Cancer</i> , 2015, 15, 375.	1.1	18
25	Simultaneous spatiotemporal tracking and oxygen sensing of transient implants in vivo using hot-spot MRI and machine learning. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 4861-4870.	3.3	18
26	Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113920.	6.6	18
27	Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. <i>BMC Cancer</i> , 2010, 10, 487.	1.1	12
28	Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 115-126.	0.9	10
29	Cell Delivery: Core-Shell Hydrogel Microcapsules for Improved Islets Encapsulation ( <i>Adv. Healthcare Tj ETQq1 1 0,784314 rgBT /Over</i> )	3.9	4
30	Less fibrosis around softer silicone implants. <i>Nature Biomedical Engineering</i> , 2021, 5, 1407-1408.	11.6	3
31	Vascularized Muscle Flap to Reduce Wound Breakdown During Flexible Electrode-Mediated Functional Electrical Stimulation After Peripheral Nerve Injury. <i>Frontiers in Neurology</i> , 2020, 11, 644.	1.1	1
32	Circumventing immune rejection and foreign body response to therapeutics of type 1 diabetes. , 2021, , 215-250.		1
33	MAP-ing a way towards tissue repair. <i>Nature Materials</i> , 2021, 20, 452-453.	13.3	0
34	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. <i>Cellular and Molecular Bioengineering</i> , 2021, 14, 471-486.	1.0	0
35	hTERT-promoter driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. <i>Human Gene Therapy</i> , 2008, .	1.4	0